期刊文献+

ADAM9 decreases in castration resistant prostate cancer and is a prognostic factor for overall survival 被引量:1

ADAM9 decreases in castration resistant prostate cancer and is a prognostic factor for overall survival
原文传递
导出
摘要 Background A disintegrin and metalloprotease 9 (ADAM9) is a membrane-anchored enzyme which is considered to be involved in some diseases including tumor. However, the role of ADAM9 in castration resistant prostate cancer (CRPC) is not clear. This study aimed to explore the different expressions on protein and messenger RNA (mRNA) level of ADAM9 between hormonal sensitive prostate cancer (HSPC) and CRPC tissue, and find the correlation with prognosis. Background A disintegrin and metalloprotease 9 (ADAM9) is a membrane-anchored enzyme which is considered to be involved in some diseases including tumor. However, the role of ADAM9 in castration resistant prostate cancer (CRPC) is not clear. This study aimed to explore the different expressions on protein and messenger RNA (mRNA) level of ADAM9 between hormonal sensitive prostate cancer (HSPC) and CRPC tissue, and find the correlation with prognosis.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第21期3800-3805,共6页 中华医学杂志(英文版)
基金 This study was supported by grants from Shanghai Cancer Center Foundation, the Natural Science Foundation of China (No. 30973009), and the Shanghai National Natural Science Foundation (No. 1 lZR1407400)
关键词 A disintegrin and metalloprotease 9 castration resistant prostate cancer immunohistochemistry qR T-PCR prognostic factor A disintegrin and metalloprotease 9," castration resistant prostate cancer," immunohistochemistry,qR T-PCR prognostic factor
  • 相关文献

参考文献1

二级参考文献28

  • 1Bolla M,van Poppel H,Collette L,van Cangh P,Vekemans K,Da Pozzo L,et al.Postoperative radiotherapy after radical prostatectomy:a randomized controlled trial (EORTC trial 22911).Lancet 2005; 366:572-578.
  • 2Freedland S J,Humphreys EB,Mangold LA,Eisenberger M,Dorey FJ,Walsh PC,et al.Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.JAMA 2005; 294:433-449.
  • 3Wiegel T,Bottke D,Steiner U,Siegmann A,Golz R,Storkel S,et al.Phase Ⅲ postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen:ARO 96-02/AUO AP 09/95.J Clin Oncol 2009; 27:2924-2930.
  • 4Kane CJ,Amling CL,Johnstone PA,Pak N,Lance RS,Thrasher JB,et al.Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.Urology 2003; 61:607-611.
  • 5Stephenson A J,Scardino PT,Kattan MW,Pisansky TM,Slawin KM,Klein EA,et al.Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.J Clin Oncol 2007; 25:2035-2041.
  • 6Wiegel T,Lohm G,Bottke D,Hocht S,Miller K,Siegmann A,et al.Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome:results of a retrospective study.Int J Radiat Oncol Biol Phys 2009; 73:1009-1016.
  • 7Moreira DM,Jayachandran J,Presti JC Jr,Aronson WJ,Terris MK,Kane CJ,et al.Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy:results from the SEARCH database.BJU Int 2009; 104:1452-1456.
  • 8Tomita N,Kodaira T,Furutani K,Tachibana H,Nakahara R,Mizoguchi N,et al.Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy.J Cancer Res Clin Oncol2009; 135:1561-1567.
  • 9Jacinto AA,Fede AB,Fagundes LA,Salvajoli JV,Castilho MS,Viani GA,et al.Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy:outcome and prognostic factors for patients who have never received hormonal therapy.Radiat Oncol 2007; 2:8.
  • 10Messing EM,Manola J,Sarosdy M,Wilding G,Crawford ED,Trump D.Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with nodepositive prostate cancer.N Engl J Med 1999; 341:1781-1788.

共引文献2

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部